Deal Watch: Tarsus Seeks Another Ophthalmology Buy With Alkeus Takeout Bid
Plus deals involving Arcturus/CSL, Harrow/Viatris, Evotec/Odyssey, Processa/Vidya, Scancell/Neuphoria as well as the latest technology transfer agreements.
Scrip - August 7, 2026

RESULTS Act Picks Up More Bipartisan Support As Medicare Lab Payment Reform Push Continues
ACLA's Susan Van Meter argues that PAMA's flawed data pushed Medicare lab reimbursement below market — and that the bipartisan RESULTS Act would fix it by using a qualified independent claims database to set payment rates while limiting future reimbursement cuts to 5%.
Medtech Insight - August 7, 2026

SMID Cap Earnings In Brief: Sarepta, Arcturus, Iovance, BioMarin, Viridian & Roivant
Sarepta’s revenues fell as Michael Severino took the CEO role; Arcturus took back rights to its mRNA COVID-19 vaccine; Iovance and Viridian saw encouraging signs for their approved products; and Roivant is getting ready to launch brepocitinib.
Scrip - August 7, 2026

Kenvue Maintains Growth Before K-C Acquisition
Q2 results Kenvue include overall net sales increasing 2.2% to nearly $4bn in what could be its final quarterly report with Kimberly-Clark’s acquisition expected to close during Q4.
HBW Insight - August 7, 2026

IPF Pipeline’s Next Big Readout: Bristol’s Admilparant Pivotal Trial
In a disease with slow therapeutic progress, Boehringer Ingelheim’s Jascayd launch progress raises interest in Bristol Myers Squibb’s admilparant and other late-stage idiopathic pulmonary fibrosis candidates.
Scrip - August 7, 2026

Kirin’s $1.4bn Jamieson Deal Signals Growing Premium For Trusted North American Supplements
Japan's Kirin has snapped up Canada's Jamieson Wellness. Not only is Kirin acquiring a North American supplements platform but a portfolio of products built on over a century of consumer trust in the Jamieson brand.
HBW Insight - August 7, 2026

Could The UK Be The First To Switch GLP-1s To OTC?
Exclusive interview: The UK MHRA’s Julian Beach says there are "no automatic noes" when it comes to Rx-to-OTC switch. HBW Insight asks what that means for GLP-1 weight loss drugs – arguably the biggest consumer health disruptor in a generation.
HBW Insight - August 7, 2026

Another Record Quarter For Terumo As Growth Strategies Gain Pace
New organ tech business in growth and company gets JPY13bn US tariff refund
Medtech Insight - August 7, 2026

Sonomind’s Mental Health Innovation Gets The Plaudits At French Medtech Start-Up Awards
France’s 11th annual medtech start-up awards in Paris yielded a standout winner in Sonomind, developer of mental health ultrasound, while BlueBack’s sensor-based real- time pelvic floor monitoring device took the CSR award.
In Vivo - August 7, 2026

Strong Q2 For Zimmer Biomet As Acquisitions, US Restructure Bear Fruit
Monogram and Paragon 28 acquisitions, plus strong hip product sales, help Zimmer Biomet raise its guidance for FY 2026.
Medtech Insight - August 7, 2026

GRAIL Bets Its Galleri Panel Will Set The FDA Bar For Future MCEDs
The advisory committee is the defining catalyst: GRAIL expects an FDA panel later this year and still eyes approval in early 2027. The review will center on Galleri's own data, but management is betting a favorable outcome sets the approval bar for the whole MCED field.
Medtech Insight - August 7, 2026

Executives On The Move: Five CEOs And Six CMOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Cyllene Therapeutics, Secretome Therapeutics and Ascentage Pharma, plus Kymera Therapeutics gets a new CMO from Johnson & Johnson.
Scrip - August 7, 2026

Viatris Raises Outlook Despite $150m Manufacturing Hit
Viatris has raised its 2026 outlook despite a manufacturing disruption set to cost up to $150m in second-half sales, as stronger complex generics, transdermals and cost savings offset pressure from lower-margin products.
Generics Bulletin - August 7, 2026

EU Urged To Reject ‘Industrially Unviable’ Export Restrictions
Medicines for Europe has urged the CJEU to reject limits on the SPC manufacturing waiver involving export storage, third-country marketing authorizations and foreign patent rights.
Generics Bulletin - August 7, 2026

Diversification Gives Fresenius Kabi Room To Absorb Manufacturing Setbacks
Fresenius Kabi’s faster-growing businesses are overtaking its legacy pharma operations, helping offset fresh FDA scrutiny at Melrose Park as the firm’s Biopharma unit helps drive stronger financials.
Generics Bulletin - August 7, 2026

Aurobindo Claims 5-7 Year Headstart With A1 Biochem, Lannett Acquisitions
The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required.
Scrip - August 7, 2026

Biocon Bullish On US Eylea Biosimilar, Says Regulatory Shift Sharpens Edge For Incumbents
Biocon expects to make the headstart for its Eylea biosimilar in the US count and indicates that its product pipeline stands to gain from recent regulatory streamlining.
Scrip - August 7, 2026

Video Podcast - Proof of Concept: AI in Drug Discovery
Can AI and simulation make the earliest, riskiest decisions in drug discovery faster and more reliable?
In Vivo - August 7, 2026

EU PPWR’s Two-Role Split Creates Costly Compliance Trap For Device Makers
The EU PPWR separates packaging compliance into two distinct roles — manufacturer and producer — with very different obligations. Conflating them is the most common error lawyers see, and it can mean absorbing EPR costs that were never yours to carry.
Medtech Insight - August 7, 2026